Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
Miruna Grecea,1 Olga Soritau,2 Daniel Dulf,1,2 Tudor Eliade Ciuleanu,1,2 Mihnea Zdrenghea2,3 1Iuliu Hatieganu University of Medicine and Pharmacy, Department of Oncology, Cluj-Napoca, Romania; 2Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Romania; 3Iuliu Hatieganu University of Medicin...
Saved in:
Main Authors: | Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/c2900d088b2e4e429ffb9a4c5748f9b3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021) -
The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps
by: Silvia Gitto, et al.
Published: (2021) -
Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
by: Robert A. Szczepaniak Sloane, et al.
Published: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2021) -
Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
by: Xin Zheng, et al.
Published: (2021)